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Introduction
Hereditary spastic paraplegia (HSP) encompasses a heterogeneous group of 
neurodegenerative diseases of genetic origin that are clinically characterized by 
progressive spasticity and weakness of lower limbs (1). Hereditary spastic paraplegia 
(HSP) is also called familial spastic paraparesis and Strümpell-Lorrain syndrome.
HSP causes degeneration of the ends of the corticospinal tracts within the spinal 
cord. The ends of the longest fibers, which supply the lower extremities, are affected 
to a much greater extent than are the fibers to the upper body. Although some 
degeneration of the fibers supplying the arms commonly takes place, most people 
with HSP do not have symptoms in hands or arms.
Pyramidal weakness with hyperreflexia and extensor plantar reflexes is the key 
diagnostic clinical findings. The genetics of HSP are complex and all mendlian 
modes of inheritance (X-Linked, autosomal dominant and autosomal recessive) 
have been discovered (2).
The prevalence of HSP worldwide is unknown, but few studies on the epidemiological 
status of HSP in Europe show a prevalence of 3-10 cases per 100000 population 
(3,4).Our experience in Mofid Children Hospital in Tehran shows that it is not a rare 
disease , probably due to the high prevalence of consanguineous marriages in Iran.
The disease begins from early childhood through to 70 years of age and therefore is a 
major source of neurodisability. In this review, we discuss its clinical and diagnostic 
features as well as the genes that have been identified and the pathophysiology of 
the disease.
Clinic and paraclinic
HSP has been traditionally divided into pure (uncomplicated) and complicated 




Hereditary Spastic Paraplegia (HSP) is a degenerative disease of genetic origin 
affecting the corticospinal tracts in the spinal cord. There are three forms of 
inheritance: Autosomal dominant HSP, Autosomal rececive HSP and X-linked 
HSP. 
This disease is characterized by progressive spasticity of leg muscles with varying 
degrees of stiffness and weakness of other muscle groups. In this review, we 
will discuss the latest findings on the pathophysiology of axonal degeneration 
and all the responsible genetic defects in HSP. 
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types, depending on the presence of concomitant and 
neurological findings in addition to spastic paraplegia. 
Spasticity is an increase in muscle tone with resulting 
stiffness. Muscle tone refers to the mild contraction that 
muscles continue to have even when at rest. A reflex 
between nerve endings in the muscle and spinal cord 
regulates muscle tone. Normally, the corticospinal nerves 
control and reduce sensitivity of this reflex. Because 
HSP causes deterioration of the corticospinal nerves, the 
reflex is not reduced as it should be, the result being an 
exaggerated reflex and increased muscle tone (5).
 The disease onset is subtle with progressive leg stiffness 
or abnormal wear of the shoes (6). Increasing stiffness 
in legs is associated with frequent tripping, particularly 
when the patient is walking on uneven terrain. 
Uncontrollable shaking of the legs may be noted during 
ambulation. Dragging of the feet, scissoring of the legs 
during walking, weakness and giving way at the ankles, 
flexor spasms of the legs during the night, and a sense 
of unsteadiness during ambulation are also common (5). 
A common symptom of HSP is a decreased sense of 
balance. For many people, this is the first symptom that 
they notice. Many people with HSP have an impaired 
sense of position in their feet. If the brain does not receive 
accurate signals about the body’s position, it may not be 
able to respond properly to those signals, and loss of 
balance occurs. The patient’s gait shows a circumduction 
pattern owing to a difficulty with hip flexion and ankle 
dorsiflexion.
Neurologic examination reveals crossed adductor 
reflexes, ankle clonus, and extensor plantar responses. 
Hoffman and Tromner signs may be observed. High-
arched feet (pes cavus) are generally present and are 
usually prominent in older patients (5).
No evidence of cranial nerve dysfunction, reduced 
cognition, speech disturbance, difficulty swallowing, 
or frank corticobulbar tract dysfunction is noted in 
uncomplicated forms. Upper extremity muscle tone and 
strength are usually normal. In the lower extremities, 
muscle tone is increased at the hamstrings, quadriceps, 
and ankles. Results of manual muscle testing are 
difficult to assess because of the increased tone; 
however, weakness is occasionally demonstrated in the 
legs. Weakness is most notable at the iliopsoas muscles, 
the tibialis anterior muscles, and, to a lesser extent, the 
hamstring muscles. Muscle wasting may occur in patients 
with pure HSP, but is mild and limited to atrophy of 
the shins in the elderly, wheelchair-dependent patients. 
Peripheral nerves are normal in patients with pure HSP, 
although decreased perception of sharp stimuli below 
the knees is occasionally noted. Vibratory sensation is 
often mildly diminished in the distal lower extremities. 
When it occurs, this deficit provides a diagnostic sign 
that helps to distinguish HSP from other disorders. 
Slight terminal dysmetria is occasionally observed on 
finger-to-nose testing in older affected individuals. Deep 
tendon reflexes may be brisk (2+ to 3+) in the upper 
extremities but are pathologically increased (3+ to 4+) 
in the lower extremities. Some people also experience 
incontinence (sense of urgency even when bladder is not 
full) (e medicine).
In comparison with other etiologies of spastic paraplegia 
(spinal injury and MS), muscle power is relatively 
preserved despite the significant increased tone in the 
legs, particularly in patients with an early-onset disease 
(1). 
Etiologic approach to any spastic paraplegia is based 
upon age and nature of the disease, onset, progression of 
symptoms, presence of a family history and associated 
clinical findings. Onset in infancy with delayed motor 
milestones is more suggestive of cerebral palsy, 
especially if there is a static clinical course.
In pure forms of HSP, some other clinical findings have 
been described: mild sensory abnormalities of the lower 
limbs (reduced vibration sense), urinary symptoms 
(reported in up to 50% of the cases in later disease), Pes 
cavus, and a mild cognitive decline. Upper limbs might 
show hyper-reflective, but cranial nerves are rarely 
involved in HSP (1-6).
Complicated HSP describes a large group of conditions 
in which spastic paraplegia is accompanied by other 
clinical signs and symptoms such as optic atrophy, 
pigmentary retinopathy, ataxia, mental retardation, severe 
amyotrophy, deafness, dementia, epilepsy, peripheral 
neuropathy, extrapyramidal signs and icthyosis (2-6).
Patients with HSP may have several possible 
complications including the following: Gastrocnemius-
soleus contracture, cold feet, fatigue, back and knee 
pain, stress and depression, which should be treated 
appropriately.
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These forms are often autosomal recessive and rare in 
North America and Europe. We should be aware that the 
presence of additional neurological findings plus spastic 
paraplegia might indicate other possible diagnoses.  
The following list denotes some major differential 
diagnoses of HSP in children: Structural abnormalities 
of the brain or spinal cord, Leukodystrophy, B12 
deficiency, Tropical spastic paraplegia (caused by 
HTLV1 infection), Dopa-responsive dystonia (also 
known as hereditary progressive dystonia with marked 
diurnal variation or “Segawa disease”),Amyotrophic 
lateral sclerosis (ALS), Primary lateral sclerosis (PLS), 
Arginase deficiency, Friedreich ataxia, and Machado-
Joseph disease (SCA3)(1).
A significant proportion of undiagnosed patients with 
spastic paraplegia are likely to be of genetic origin, and 
detailed family history is therefore crucial. The presence 
of a slowly progressive gait disorder with relatively few 
sensory symptoms or signs favors the diagnosis of HSP. 
Acute or sub acute onset of spasticity favors vascular 
or inflammatory causes, respectively, and in these cases 
weakness is often more marked. Similarly, spinal cord 
compression also has a more aggressive course, often 
accompanied by sensory signs and symptoms plus spinal 
or referred pain, which is unusual in HSP (1).
In a family with several affected members, it is easy to 
make the diagnosis of HSP, but for a patient to whom 
there is no reliable or verifiable family history, further 
investigation is required. This investigation includes 
plasma amino acids, serum lipoprotein analysis, very 
long chain fatty acids, white cell enzymes, vitamin B12  
or vitamin E, copper and ceruloplasmin, serum serology 
for syphilis, human T-cell leukemia virus 1, HIV and 
neuro ophthalmological  consult (1).
The most common MRI finding in HSP is thinning of the 
cervical and thoracic spinal cord (7).
Electromyography and nerve conduction studies 
are normal in the majority of pure HSP patients (8). 
Cerebrospinal fluid analysis is also usually normal in 
HSP, although increased protein is noted in some patients. 
Central motor conduction times have been reported to 
be delayed or unrecordable from the lower limbs and 
lower extremity somatosensory evoked potentials show 
a conduction delay in dorsal column fibers (9).
Pathophysiology
The main neuropathological finding in HSP is axonal 
degeneration of the terminal portions of the long 
descending (corticospinal tracts) and ascending (dorsal 
columns) pathways in the spinal cord (10). Studies on 
some genes implicated in hereditary spastic paraplegia 
have revealed that membrane trafficking and axonal 
transport defects are implicated in many cases of HSP 
(11). As a result of the unique morphology of spinal 
neurons, the long axons (which can measure up to 1 m 
in length) are likely to have considerable dependence on 
membrane trafficking, microtubule-associated transport, 
and cytoskeletal organization. Membrane trafficking 
and axonal transport depend on the appropriate function 
of mitochondrial function. Thus, membrane traffcking, 
axonal transport, mitochondrial function and their 
meticulous interaction are potentially important factors 
in HSP pathophysiology (figure 1)(11).
Membrane trafficking (1): All cells have a regulated, 
dynamic membrane traffcking system that allows 
interactions between the plasma membrane and other 
membrane-bound compartments. This traffcking is highly 
organized and starts with vesicle budding,  followed by 
transport of the vesicle, tethering, and fusion with the target 
membrane. Endocytosis begins with vesicle formation at 
the plasma membrane which contains receptors and/or 
other transmembrane proteins and is reliant on the vesicle 
coat protein, clathrin. Vesicles are transported along 
the microtubule cytoskeleton, as described below, and 
then tethering and fusion of endosomes occur to deliver 
cargo to various sub-cellular locations. These processes 
depend on families of proteins, such as the Rab family of 
small GTPases, that mediate the intracellular destination 
of the vesicles and ESCRT (endosomal sorting complex 
required for transport)-associated proteins, which sort 
proteins targeted for ubiquitin-dependent degradation. 
The secretory pathway flows in the opposite direction 
to endocytosis, from the endoplasmic reticulum (ER) 
and Golgi apparatus, and allows the delivery of newly 
synthesized proteins, carbohydrates, and lipids to the 
cell surface, endosomes, and lysosomes.
Axonal transport (1): Axonal transport mainly 
depends on microtubule tracks and is powered by two 
distinct classes of molecular motors, namely dynein 
(retrograde transport) and kinesins (mainly anterograde 
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transport). Cytoplasmic dynein is a ubiquitous motor 
of the AAA (ATPase associated with various cellular 
activities) family, and comprises many subunits that are 
responsible for attachment to microtubules and cargo 
recruitment. Dynein is necessary for a wide variety 
of cellular processes, such as cell division and Golgi 
maintenance, and neurons are highly dependent on the 
proper function of this molecular complex for their 
axonal transport. Indeed, dynein has been shown to be 
involved in the axonal transport of numerous cargoes, 
such as neurotrophin-signalling endosome. The kinesin 
family comprises several members, some of which 
are responsible for the delivery of material to nerve 
terminals. Kinesin 1 is composed of two kinesin heavy 
chains and two kinesin light chains. The maintenance 
of the cytoskeletal tracks also depends on molecular 
motors, which are responsible for the transport of short 
microtubules and neurofilaments to where they are 
required for growth and repair.
Important components of the process of microtubule 
remodeling are those proteins that divide microtubules 
into short lengths.
8 HSP genes: Spastin (SPAST), Atlastin GTPase1 (ATL1), 
Kinesin Family Member 5A (KIF5A), Non imprinted 
in Prader-Willi/Angelman syndrome1 (NIPA1), Zinc 
Finger FYVE domain-containing 26 (ZFYVE26), 
SPG20, SPG21 and SPG11 support dysfunction of axonal 
transport and membrane trafficking as causes of HSP 
(11). SPAST-associated cases account for approximately 
40% of autosomal dominant HSP patients, making 
mutation in these genes the most common cause of HSP. 
Over 150 mutations have been described in SPST which 
encodes spastin, a member of the ATPase-Associated 
(AAA) family of proteins, which is a component of the 
dynein motor and is involved in axonal retrograde Cargo 
transport (12). Different SPAST mutations lead to either 
haploinsufficiency or gain of function (13). Mutations in 
another gene, ATL1, cause ~ 10% of autosomal dominant 
HSP cases with an early-onset pure phenotype (SPG3A) 
(14). The primary role of Atlastin 1 is in endoplasmic 
reticulum and Golgi morphogenesis, but it also has a 
role in neurite outgrowth (15). Interestingly, Atlastin 
and Spastin directly interact, which suggests a common 
pathway of HSP pathogenesis. HSP cases associated with 
KIF5A (SPG10) were initially only reported in early-
onset pure HSP. But recently, mutations were reported in 
10% of cases of complicated HSP in patients of European 
descent (16). KIF5A is a sub unit of Kinesin 1 and in 
vitro studies indicate that expression of its mutant forms 
leads to reduced Cargo flux along microtubules.
Mitochondrial function (11): Three HSP causative genes 
(SPG7, heat shock 60-kDa protein 1 (HSPD1) and 
Receptor Expression-Enhancing Protein 1 (REEP1)) 
support a role for mitochondrial dysfunction. Mutations 
in SPG7, which encodes paraplegin, account for ~5% 
of autosomal recessive HSPs. These mutations produce 
both pure and complicated HSP forms (17). Paraplegin 
is part of the metalloprotease AAA complex, which is 
an ATP-dependent proteolytic complex that is located 
on the inner mitochondrial membranes and that controls 
protein quality and ribosomal assembly (18). 
The disease is due to the loss of Paraplegin function and 
both axonal transport and mitochondrial dysfunction may 
be implicated. SPG13 cases are associated with HSPD1, 
which participates in the folding of mitochondrial 
proteins, and are usually late-onset, pure forms (19).
Other cellular dysfunction in HSP: Two HSP causative 
genes, L1 Cell Adhesion Molecule (L1CAM) and 
Proteolipid Protein 1 (PLP1)), which underlie two X-
linked forms of HSP encode membrane myelin proteins 
expressed in schwan cell. The L1CAM-associated HSP 
(SPG1) is the most common form of complicated HSP 
(11). Mutations in cytochrome P450, family 7, subfamily 
b, polypeptide 1 (CYP7B1) are found in families 
with autosomal recessive HSP (SPG5A). SPG5A was 
originally viewed as a pure HSP form with a variable 
age of onset and slow progression, but it is now believed 
to have both pure and complex forms. CYP7b1 mutants 
are proposed to affect cholesterol homeostasis because 
the normal protein is involved in myelin formation (20). 
Genetic
The various Spastic Paraplegia (SPG) loci are associated 
with different forms of HSP which are listed in table 1 and 
recently, 45 SPG loci and 20 causative genes have been 
identified (B). The identification of these genes has led 
to insight into potential pathological mechanisms. HSP 
can be inherited as an autosomal dominant, recessive, or 
X-linked recessive trait .Autosomal dominant HSP is the 
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most prevalent form and represents around 70% of the 
cases. Most cases of pure HSP are autosomal dominant, 
whereas complicated forms tend to be autosomal 
recessive. We will describe clinical phenotypes of more 
common genetic subtypes of HSP in the following 
paragraphs.
Autosomal dominant HSP 
SPAST-associated HSP (SPG4) is the most common 
type (40–45%) of pure autosomal dominant HSP and 
is the form that has been clinically more studied. The 
onset SPAST-associated HSP is usually in childhood 
through to late adult life (21).  Overall, more than half 
of mutation carriers do not develop symptoms until 
after the age of 30 years. In most cases, the phenotype 
is slowly progressive spasticity in the lower limbs with 
loss of mobility around two decades after the onset of 
symptoms. Symptoms consistently found in a small 
number of patients with a longer disease duration include 
urinary urgency, upper limb hyper-reflexia, decreased 
vibration sense, and muscle wasting in the lower limbs 
(21).Complex phenotypes, including cerebellar ataxia, 
epilepsy, thinning of the corpus callosum, and mental 
retardation, have been described in several families with 
a mutation in the SPAST gene which encodes the Spastin 
Protein (1). 
SPG3A-associated HSP is the second most common 
cause of autosomal dominant HSP, accounting for 
approximately 10% of the cases (22). It usually has a 
pure phenotype but an earlier onset, often before the 
age of 10 years. Typically, symptoms progression is 
relatively slow. 
Mutations in NIPA1 (formerly SPG6) are also a cause of 
pure HSP that progresses slowly but can become severe 
(23). Penetrance is age dependent and high. Similarly, 
HSP associated with mutations in KIAA0196 (formerly 
SPG8) is characterized by more severe spasticity and a 
reduced vibration sense. HSP associated with mutations 
in the gene for Heat Shock Protein 60 (HSPD1; formerly 
SPG13) typically has a late onset without additional 
features (19). A Gly563Ala missense variant was 
recently reported to be associated with an earlier age of 
onset in patients carrying SPAST mutations, although 
this was not pathogenic by itself. Mutations in BSCL2 
(formerly SPG17) cause a complicated form of HSP that 
is characterized by additional amyotrophy of the small 
muscles of the hands and feet with onset in the early teens 
to the late thirties (Silver syndrome). Mutations in the 
BSCL2 gene also cause hereditary motor neuropathy type 
V and the autosomal recessive condition Berardinelli-
Seip congenital lipodystrophy (1). Mutations in REEP1 
(formerly SPG31) lead to a pure form of HSP with a 
variable age of onset. It is relatively common, and 
mutations in the REEP1 gene have been identified in 
3% of a sample of unrelated patients with HSP, which 
increased to 8·2% in pure HSP if those with SPG3A and 
SPAST mutations were excluded (24). Other forms of 
autosomal dominant HSP are summarized in the table 
(associated with KIF5A, SPG9, SPG12, SPG18, SPG19, 
SPG29, SPG34, SPG36–SPG38, and SPG41 genes).
 
Autosomal recessive HSP
A number of families have autosomal recessive HSP that 
is associated with mutations in the CYP7B1 (formerly 
SPG5A) gene. This is a pure form with a variable age of 
onset and slow progression. To date, it has been recorded 
in about 20 families (25). Mutations in the SPG7 gene, 
which encodes Paraplegin, account for around 5% of 
autosomal recessive HSP. This type produces both pure 
and complicated HSP phenotypes. Cerebellar signs 
(dysarthria, nystagmus, and ataxia), pale optic discs, and 
peripheral neuropathy are common complicating features 
(26). SPG11-associated HSP, which is characterized by a 
thin corpus callosum, is a common and clinically distinct 
form that is linked to the SPG11 locus on chromosome 
15 in most families. Other common features include 
cognitive impairment and severe axonal neuropathy 
(27-28). HSP associated with mutations in ZFYVE26 
(formerly SPG15) has a characteristic autosomal 
recessive complicated phenotype (Kjellin syndrome), 
in which spastic paraplegia is accompanied by mental 
impairment, pigmentary retinopathy, cerebellar signs, 
and distal amyotrophy (29).
SPG20-associated HSP and SPG21-associated HSP 
are two complicated forms that have been identified in 
members of the Old Order Amish. A single mutation in 
SPG20, which encodes the Protein Spartin, causes Troyer 
syndrome(31), whereas a mutation in SPG21 (encoding 
the Protein Maspardin) causes Mast syndrome(32). 
Troyer syndrome is characterized by spastic tetraparesis, 
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dysarthria, distal amyotrophy, short stature, and learning 
difficulty. Mast syndrome is associated with dementia, 
cerebellar and extrapyramidal signs, and thin corpus 
callosum. 
The remaining recessive forms of HSP (associated with 
SPG14, SPG23–SPG28, SPG30, SPG32, SPG35, and 
SPG39) are very rare, and have each been described in 
only one or two families. Any distinguishing clinical 
feature is listed in the table 1. 
X-linked HSP 
HSP caused by mutations in L1 Cell Adhesion Molecule 
(L1CAM) (formerly SPG1) is characterized by 
spasticity of the legs, mental retardation, hydrocephalus, 
and adducted thumbs. L1CAM is a transmembrane 
glycoprotein protein that is expressed in neurons and 
schwann cells and is believed to have a role in the 
development of the central nervous system (CNS). The 
phenotypic spectrum of L1 syndrome also includes X-
linked hydrocephalus with aqueduct of Sylvius stenosis, 
MASA syndrome (mental retardation, aphasia, spastic 
paraplegia, and adducted thumbs), and X-linked agenesis 
of the corpus callosum (30). 
Mutations in the Proteolipoprotein gene (PLP1; formerly 
SPG2) at Xq21-q22 have been found in families with a 
mainly complicated HSP in which there can be associated 
white matter changes on MRI and peripheral neuropathy. 
Mutations (usually duplications) of this gene also give 
rise to a dysmyelinating condition known as Pelizaeus-
Merzbacher disease (PMD), which is characterized by 
congenital hypotonia, psychomotor deterioration, and 
progressive pyramidal, cerebellar, and dystonic signs. 
Death usually occurs in infancy or childhood. The 
variation in phenotype between PMD and PLP1-linked 
HSP is thought to arise from the differential effect that 
mutations can have on the two isoforms of the protein 
product, Proteolipoprotein 1 (PLP1) and DM20. Both 
are integral membrane proteins that account for ~50% 
of the protein content of adult CNS myelin. Mutations 
in exon 3b of PLP1 might predominantly result in SPG2 
rather than PMD because this exon is excluded from 
DM20, which is thought to therefore be left intact. PMD 
is thought to arise only when DM20 is also affected by 
mutation (31).
Treatment
Currently, there is no specific treatment to prevent, retard, 
or reverse HSP’s progressive disability. Nonetheless, 
treatment approaches used for chronic paraplegia from 
other causes are useful. Antispasticity medications can 
be useful. However, one of the limitations of these 
agents is that some patients find that the stiffness of 
spasticity helps them to overcome the muscle weakness 
that also occurs in HSP. When patients are medicated to 
reduce spasticity, walking may become more difficult. 
Adverse effects can also be a problem. If the patient 
does well with the medications, however, discomfort 
associated with spasticity can generally be reduced, 
mobility can be improved, and the effectiveness of 
physical therapy can be enhanced. Patients in relatively 
early stages of the illness have achieved symptomatic 
improvement with oral Dantrolene, as well as with oral 
and intrathecal Baclofen. Tizanidine has also provided 
some reduction of spasticity in HSP patients.  Tizanidine 
is a centrally acting muscle relaxant metabolized in 
the liver and excreted in urine and feces. Baclofen 
may induce hyperpolarization of the afferent terminals 
and inhibit monosynaptic and polysynaptic reflexes at 
the spinal level. Dantrolene Sodium stimulates muscle 
relaxation by modulating skeletal muscle contractions at 
the site beyond the myoneural junction and acts directly 
on muscle itself. Some patients benefit from injections 
of Botulinum toxin type A. Botulinum toxin binds to 
receptor sites on motor nerve terminals and inhibits 
the release of acetylcholine, which in turn inhibits the 
transmission of impulses in neuromuscular tissue. 
This agent is most useful for treating spasticity in the 
gastrocnemius and soleus muscles and less effective in 
larger muscles (e.g. quadriceps). Bladder spasticity may 
be improved with Oxybutynin.
Regular physical therapy (PT) is important for 
maintaining and improving range of motion (ROM) 
and muscle strength. Furthermore, PT is necessary to 
maintain aerobic conditioning of the cardiovascular 
system. Although PT does not reduce the degenerative 
process within the spinal cord, individuals with HSP must 
maintain an exercise regimen performed at least several 
times each week as guided by their physical therapist. 
Exercise can help the patient to retain or improve muscle 
strength, minimize atrophy of the muscles caused by 
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disuse, increase endurance, reduce fatigue, prevent 
spasms and cramps, and maintain or improve range 
of motion. Exercise also has a positive psychological 
effect, helping to reduce stress and produce a feeling of 
well-being. Patients with HSP may experience spasticity 
and weakness (i.e. increased muscle tone and reduced 
muscle strength). Because of the increased resistance 
to passive stretching, spasticity may make it difficult 
for patients to exercise certain muscles. Antispasmodic 
drugs may help the patient to reduce the spasticity and 
may allow weakened muscles to be targeted in order 
to improve the effectiveness of PT. Different types of 
exercises incorporated into PT programs for patients 
with HSP may include strengthening, stretching, and 
aerobic exercises, as follows:
• Strengthening exercises - These help to strengthen 
muscles that have not yet weakened. Strengthened 
muscles help to compensate for muscles that 
have weakened, decreasing the rate of functional 
impairment. Exercise may also help to slow the 
development of disuse atrophy, which occurs in 
muscles that are not being used (e.g.  calf muscles 
of the people who are wheelchair-bound). Back-
strengthening exercises may help to reduce or 
eliminate back pain associated with HSP. Such pain 
is probably not due to HSP itself but to strain on 
the back resulting from HSP (e.g. poor gait, poor 
posture, and use of a mobility device). 
• Stretching exercises - These help to maintain or 
increase ROM and to reduce such problems as 
tendinitis, bursitis, and muscle cramps. 
• Aerobic exercises - These improve cardiovascular 
fitness, reduce fatigue, and increase endurance 
and general fitness. Walking, bicycle riding, water 
aerobics, and swimming are among many excellent 
forms of aerobic exercises.
In patients with pure HSP, life expectancy is typically 
unaffected by the disease. This prognosis can not be 
generalized to complicated HSP patients, because 
each case has its own unique symptoms.
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Fig 1. Potential Pathogenic mechanisms in heredity spastic paraplegia. The genes known to predispose to hereditary spastic 
paraplegia (HSP) support the view that defects at various cellular sites can be detrimental to the long axons of upper motor 
neurons. This representation of a motor neuron shows where these HSP-predisposing proteins have been suggested to reside 
or function. Motor neurons have a regulated. Dynamic membrane-trafficking system that involves HSP-predisposing proteins 
that function in the endoplasmic reticulum (ER) and Golgi. Endosomes are transported along the microtubule cytoskeleton 
to various subcellular locations. A process that that involves HSP-predisposing proteins that are located on endosomes and 
microtubules. Motor neurons rely on mitochondria to drive the efficient transport of signals. Molecules and organelles to 
and from nerve terminals, and this process also involves HSP-predisposing proteins that function in mitochondria. For 
other HSP-predisposing proteins (for example, strumpellin, connexin 47(CX47) and cytochrome P450, family7,subfamily 
B, polypeptide1(CYP7B1): not shown). Their location is unclear and/ or their contribution to motor neuron disease in not yet 
understood. ACATN.acetyl-CoA transporter:HSP60. Heat shock protein 60: KIF5A. Kinesin family member SA: L1CAM. 
L1 cll adhesion molecule:NIPA1.non –imprinted in Prader-Willi/Angelman syndrome region protein1: PLP1.Proteolipid 
protein 1: REEP1.receptor expression-enhancing protein1 (11).
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Table 1. Genetic causes of other motor neuron disease: AD.autosomal dominant,ALS.amyotrophic lateral sclerosis: 
AR.automal recessive, BSCL2. Beradinelli-Seip  congenital contravture syndrome, MSA.mental retardation.aphasi. 
shufflinf gait and adducted thumbs,PLP1.proteolipid protein1, PLSA1.adult primary lateral sclerosis,PNPLA5.
phospholipase domain-containing6, SBMA.spinal bulbar muscular atrophy, SMA. Spinal muscular atrophy, SPG.
spstic paraplegia, ZFVEZ6.zinc finger. FYVE domain-contaning26 (11). 
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